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improved but remained of moderate severity (falling from 46
before transplant to 30 two-years after LT). Therefore we do not
believe the high fatigue scores before LT were suggestive of HE-
related fatigue. Furthermore, we did not find any correlation
between the severity of the liver disease and the severity of the
fatigue, in keeping with previous literature. Minimal HE can only
be determined by a comprehensive neurological assessment of
consciousness, cognitive, and motor function and this has not
been part of our routine pre-transplant assessment.
Kalaitzakis et al. have shown the persistence of fatigue after LT
in those with other indications. However, data from more than
half of the patients was excluded from the final analysis. As sug-
gested by Kalaitzakis et al. unidentified transplantation-related
factors may be relevant for post-transplant fatigue. However, as
shown in Fig. 3 of our paper [2], no patient developed fatigue
de novo after transplantation.
Further studies are needed to establish if the changes
seen here are unique to PBC and to identify the mechanisms
responsible for this symptom, and so develop appropriate
treatments.
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Letters to the EditorTo the Editor:
We would like to thank Kalaitzakis et al. [1] for the comments on
our article on the effect of liver transplantation (LT) on fatigue in
patients with primary biliary cirrhosis (PBC) [2]. They confirm in
an independent PBC cohort that fatigue remains a problem after
LT. They also address some important issues, such as the need for
an accurate assessment of hepatic encephalopathy (HE) before LT
in patients with PBC, and that fatigue may not be specific to PBC.
Kalaitzakis et al. [1] showed that fatigue improved after LT
although fatigue scores remained higher than in controls from
the general population. Of note, they found that the median fati-
gue impact score (FIS) after LT was 40, which is identical to the
median FIS in a non-transplant PBC cohort, reported by Goldblatt
et al. [3]. In our study [2] fatigue score, assessed using the PBC-40,
was 26 ± 10 at two years after LT, which was lower compared to a
‘non transplant’ PBC control cohort (31 ± 12; p = 0.03); however,
the fatigue score was higher than a ‘normal’ age- and sex-
matched control group (18 ± 6; p <0.0001).
The work of Kalaitzakis et al., along with our data, casts some
light on the pathophysiology of fatigue, as they suggest the
abnormalities that result in fatigue are either irreversible or that
they do not arise in the affected liver. These findings also are
helpful in identifying the role of transplantation in symptomatic
patients with PBC.
Chronic fatigue is a feature of HE and the relationship
between fatigue and HE in patients with PBC and other chronic
liver conditions is complex and not fully understood. Emerging
data suggest that continued cognitive impairment post-trans-
plant is seen in particularly in patients with recurrent encepha-
lopathy pre-transplant. This suggests that the neuropsychiatric
abnormalities of encephalopathy, as the fatigue of PBC, do not
fully revert post-transplant [4]. Larger, longitudinal studies are
required to address this issue.
In the Birmingham liver unit, HE is routinely assessed using
the Number Connection Test and graded clinically from 0–4 (West
Haven criteria). In our study no patient was excluded because of
overt HE. In the final cohort analyzed, only two had clinically evi-
dent HE who had grade 2 HE before LT. In one patient the fatigue
persisted after transplant with the same severity (PBC-40 score of
45 and 46, before and two-years after LT). In the other, the fatigue1328 Journal of Hepatology 2014 vol. 60 j 1325–1333
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Hepatocellular carcinoma and the Newcastle-upon-Tyne area
To the Editor:
The cross sectional studies of hepatocellular carcinoma (HCC) in
the Newcastle-upon-Tyne area may need further clarifications
by the authors [1].
First, how can HCC-related mortality in this region have risen
1.8 fold in 10 years, from 2.0 to 3.7 per 100.000. Indeed, over the
last decade (between 1999–2001 and 2008–2010), the UK age-
standardised incidence rates have only increased by 45% and
29% in males and females, respectively. These rates are not differ-
ent from those observed in Europe: 44% and 31% increases,
respectively (http://www.cancerresearchuk.org/cancer-info/
cancerstats/types/liver/incidence/). Why could the significant
progresses made for early diagnosis and in treatments (e.g.,
sorafenib, RFA) have lacked effect on mortality?
Second, why are Dyson et al. not concerned with smoking?
Smoking prevalence (April 2010–March 2011) is 23.8% in the
Newcastle-upon-Tyne area and therefore higher than in England
(20.7%) (http://www.newcastle.gov.uk/sites/drupalncc.newcas
tle.gov.uk/files/wwwfileroot/business/trading_standards/occa
sional_paper_no_49__smoking_prevalence_in_the_north_east__
final.pdf). It is an independent and a dose-related contributing
factor for HCC, all over the world, even in Asia [2]! The mean rel-
ative risk is 1.5 but exposure is high [3]. In France, tobacco, viral
hepatitis, and alcohol are the 3 main risk factors for HCC contrib-
uting with 33%, 31%, and 26%, respectively to HCC [4].
Last, the cause of non-alcoholic fatty liver disease is still
unknown, it is only a syndrome. Both obesity and insulin resis-
tance may play a role in the process. However, (a) liver disease
per se produces insulin resistance; (b) morbid obesity does not
appear to be a cause of liver disease in large series when other
known causes are carefully investigated [5]. Did Dyson et al.,
questioned the entourage for alcohol consumption and how they
recorded past history of medicine prescriptions, such as antide-
pressants [6,7]?
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